FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004)

作者：Alexander I. Spira, Byoung Chul Cho, Enriqueta Felip, Edward B. Garon, Kōichi Goto, Melissa Johnson, Natasha B. Leighl, Antonio Passaro, David Planchard, Sanjay Popat, James Chih‐Hsin Yang, Xiaoqian Lu, Yong Jiang, Jack Huang, Morgan Lam, Marcin Kowanetz, Shirley Wang, John T. Le, Jerry Y. Hsu, Caicun Zhou · 发表于：Lung Cancer · 年份：2024 · DOI：10.1016/j.lungcan.2024.108066 · 被引用次数：7 · 研究领域：Lung Cancer Treatments and Mutations、Colorectal Cancer Treatments and Studies、Gastric Cancer Management and Outcomes

Epidermal growth factor receptor (EGFR) exon 20 insertion mutations (ex20ins) occur in approximately 2 % of non-small cell lung cancer (NSCLC) and overall account for approximately 9 % of all the EGFR mutations in NSCLC (Robichaux et al 2021). The current first-line standard of care for NSCLC patients with these mutations is infusion of amivantamab plus carboplatin plus pemetrexed (NCCN Version 11.2024). However, there remains a need for an effective and well-tolerated chemotherapy-free treatment option for these patients.